| Literature DB >> 33078262 |
Nora-Lynn Schwerdtner1, Frank Kipp2.
Abstract
Infections caused by multidrug-resistant pathogens and their inpatient (nosocomial) and outpatient spread, pose increasing challenges to our healthcare system. Control strategies are derived from vertical (individual, pathogen-specific) and horizontal (general, pathogen-unspecific) preventive measures. The discussion of a competing "either or" has not proven to be effective in the past. In addition, the problem of multidrug-resistant pathogens cannot be solved solely in inpatient health care: the goals are a seamless communication and transparent cooperation between all actors in the healthcare system. Nowadays, modern molecular methods for pathogen typing are available, with the help of which transmission pathways can be clarified and hospital hygiene measures can be efficiently controlled. These procedures will be used increasingly more in the future to combat the problem of multidrug resistance across interfaces within regional network structures.Entities:
Keywords: Horizontal and vertical prevention measures; MDR networks; Multiple drug resistance; Nosocomial infections; Whole genome sequencing
Mesh:
Substances:
Year: 2020 PMID: 33078262 PMCID: PMC7571528 DOI: 10.1007/s00120-020-01360-0
Source DB: PubMed Journal: Urologe A ISSN: 0340-2592 Impact factor: 0.639


| Antibiotikagruppe | Leitsubstanz | ||||||
|---|---|---|---|---|---|---|---|
| 3‑MRGNa | 4‑MRGNb | 3‑MRGNa | 4‑MRGNb | 3‑MRGNa | 4‑MRGNb | ||
| Acylureidopenicilline | Piperacillin | R | R | Nur eine der 4 Antibiotikagruppen wirksam (S oder I) | R | R | R |
| Dritt‑/Viertgenerationscephalosporine | Cefotaxim und/oder Ceftazidim | R | R | R | R | R | |
| Carbapeneme | Imipenem und/oder Meropenem | S oder I | R | R | S oder I | R | |
| Fluorchinolone | Ciprofloxacin | R | R | R | R | R | |
| – | – | – | Oder Nachweis einer Carbapenemasec | – | Oder Nachweis einer Carbapenemasec | – | Oder Nachweis einer Carbapenemasec |
R resistent, I „increased“ – sensibel bei erhöhter Dosierung/Exposition, S sensibel bei normaler Dosierung
a3‑MRGN (multiresistente gramnegative Stäbchen mit Resistenz gegen 3 der 4 Antibiotikagruppen)
b4‑MRGN (multiresistente gramnegative Stäbchen mit Resistenz gegen 4 der 4 Antibiotikagruppen)
cunabhängig vom Ergebnis der phänotypischen Resistenzbestimmung für Carbapeneme sowie der anderen 3 Substanzklassen